Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results.

Abstract

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1983.1.1.66 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 6668484 Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results. I TannockxI TannockSearch for articles by this author , K MurphyxK MurphySearch for articles by this author https://doi.org/10.1200/JCO.1983.1.1.66 First Page PDF © 1983 by American Society of Clinical Oncology

References

Page 1

	Year	Citations
The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control Trial Jennie A. Freiman, Thomas C. Chalmers, Harry Smith, New England Journal of Medicine	1978	1.6K
Randomized versus historical controls for clinical trials Henry S. Sacks, Thomas C. Chalmers, Harry Smith The American Journal of Medicine Clinical Trial DesignClinical Trial ManagementClinical TrialsVersus Historical ControlsRandomized Controlled Trial	1982	833
Prognostic Factors for Survival in Patients With Inoperable Lung Cancer<xref ref-type="fn" rid="FN2">2</xref> Kenneth Stanley JNCI Journal of the National Cancer Institute Prognostic FactorsSeventy-seven Prognostic FactorsAdvanced Lung DiseasePrognosisOncology	1980	565
The effect of measuring error on the results of therapeutic trials in advanced cancer Charles G. Moertel, James A. Hanley Cancer Surgical OncologyCancer ManagementClinical EndpointTherapeutic TrialsOncology	1976	254
Scientific problems in clinical scales, as demonstrated in the karnofsky index of performance status Tom A. Hutchinson, Norman F. Boyd, Alvan R. Feinstein Journal of Chronic Diseases ReliabilityScaling AnalysisEngineeringHuman Performance MeasuringClinical Scales	1979	238
Commentary: current status of chemotherapy for non-small cell lung cancer. Joseph Aisner, Hansen Hh PubMed MedicineMetronomic TherapyPathologyBronchial NeoplasmCancer Treatment	1982	102
Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine. A. Philippe Chahinian, Daniel J. Arnold, James M. Cohen, PubMed OncologyCombination ChemotherapyMedicineObjective Response RatePathology	1977	53
MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung.Low response rate in a cooperative group study Steven E. Vogl, Cyrus R. Mehta, Martin H. Cohen Cancer	1979	37
Failure of short-course multiple drug chemotherapy to benefit patients with recurrent or metastatic head and neck cancer Ian F. Tannock, Donald Sutherland, David Osoba Cancer Advanced CancerNeck CancerOncologyFifty-seven PatientsRadiation Therapy	1982	27
Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer. Knost Ja, Greco Fa, Hande Kr, PubMed Cancer ManagementPathologyFifty-four PatientsPharmacotherapyMetronomic Chemotherapy	1982	27

Page 1